Gastric Cancer Market: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

Tuesday, December 20, 2016 8:34 AM UTC

Dublin, Dec. 20, 2016 -- Research and Markets has announced the addition of the "Gastric Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer.

This report addresses the following questions:

- What impact will the PD-1/PD-L1 inhibitor class of drugs have on the gastric cancer market?
- How will pipeline immunotherapies be positioned in the gastric cancer treatment space?
- Which targeted therapies are expected to experience the greatest growth over the forecast period?
- How will Eli Lilly look to maintain Cyramza's first-to-market advantage?
- What are the key drivers of the rapidly expanding gastric cancer market?

Key Topics Covered:

FORECAST: GASTRIC CANCER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Avelumab
- BBI
- (napabucasin)
- Cyramza (ramucirumab)
- GS-57

- Herceptin (trastuzumab)
- Keytruda (pembrolizumab)
- Lynparza (olaparib)
- Nimotuzumab
- Opdivo (nivolumab)
- Perjeta (pertuzumab)
- Primary Research Methodology

TREATMENT: GASTRIC CANCER

- Executive Summary
- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: GASTRIC CANCER

- Executive Summary
- Product Overview
- Product profile: Cyramza
- Product profile: Herceptin

PIPELINE: GASTRIC CANCER

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): BBI6
- Product profile (late stage): GS-57
- Product profile (late stage): Keytruda
- Product profile (late stage): Lynparza
- Product profile (late stage): Opdivo
- Product profile (late stage): Perjeta
- Product profile (late stage): avelumab
- Product profile (late stage): nimotuzumab

For more information about this report visit http://www.researchandmarkets.com/research/m6cxm5/gastric_cancer



CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Oncology Drugs

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Gastric Cancer Market: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

Editor's Picks

Welcome to EconoTimes